
The study aimed to assess the effectiveness and safety of regorafenib, either alone or combined with an immune checkpoint inhibitor, in treating metastatic colorectal cancer (mCRC) in Chinese patients. Retrospective data analysis from 537 patients treated at ten Chinese hospitals revealed that the combination therapy led to significantly longer overall survival than regorafenib monotherapy without a notable increase in adverse events. The real-world evidence supports the adoption of regorafenib plus an immune checkpoint inhibitor as a viable later-line treatment for mCRC in Chinese patients
Like
Save
Share